News archive
Showing 785 results
October 2015
September 2015
-
Media Release
Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis
-- In the FUTURE 1 study, secukinumab met the primary endpoint showing statistically significant efficacy versus placebo in improving signs and symptoms of active psoriatic arthritis (PsA)-- All pre-… -
Media Release
Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis
-
Media Release
Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®
Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar + MekinistTafinlar + Mekinist combination also demonstrated… -
Media Release
Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®
-
Media Release
Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries
- First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and… -
Media Release
Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries
July 2015
-
Media Release
FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
- Approval is based on pivotal Phase II study in which objective response rate (ORR) in patients with laBCC was 58%; responses were durable(1)- Basal cell carcinoma, the most common form of skin… -
Media Release
FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
-
Media Release
Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril/valsartan)
- First in the world approval brings hope of longer life and fewer HF hospitalizations by reducing the devastating impact of heart failure with reduced ejection fraction for millions of patients in… -
Media Release
Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril/valsartan)
First in the world approval brings hope of longer life and fewer HF hospitalizations by reducing the devastating impact of heart failure with reduced ejection fraction for millions of patients in the…